Clinical Trials Logo

Filter by:
NCT ID: NCT05157919 Completed - Critical Care Clinical Trials

Mobile App to Promote Family Caregiver Engagement in the Intensive Care Unit

ICU-CARE
Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled pilot trial is to develop and test mobile app, Intensive Care Unit-Caregiver Activation Response, and Engagement (ICU-CARE). ICU-CARE provides a simulated learning environment to encourage family caregivers of mechanically ventilated patients to assess two patient symptoms, thirst and anxiety, and perform specific nonpharmacologic comfort measures to help alleviate patient symptom burden.

NCT ID: NCT05157841 Completed - Hallux Valgus Clinical Trials

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

Start date: February 10, 2022
Phase: Phase 3
Study type: Interventional

The study is conducted sequentially in two parts. Part A: The purpose is to obtain information on PK profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL. Part B: The purpose is to evaluate the efficacy and safety of the preferred dosage of EXPAREL from Part A compared with bupivacaine HCl.

NCT ID: NCT05157399 Completed - Dizziness Clinical Trials

Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness

Start date: November 4, 2021
Phase: N/A
Study type: Interventional

Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population. Vestibular disorders have a dramatic impact on daily life impacting work, relationships, and even activities of daily living.The OtoBand has shown promise and might be beneficial for treating or improving the course of recovery from vestibular disorders. This study seeks to quantify the effect of the study device, the OtoBand, on objective measures of dizziness and vertigo in patients with vestibular dysfunction. The study will be conducted at a single-site and will be a blinded, randomized, placebo-controlled design in which participants do not know if they are receiving bone conducted stimulation 1) at a therapeutic level or 2) at a non therapeutic level.

NCT ID: NCT05157191 Completed - Pain Clinical Trials

Safety of Pediatric COVID-19 Vaccination

Start date: April 6, 2022
Phase:
Study type: Observational

This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to < 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the 7 days following each vaccination using either identical web-based or paper diaries, depending on study participant preference. At Duke University, Cincinnati's Children Hospital, and Kaiser Permanente Northern California, serum samples will be collected for optional assessment of antibody titers to COVID-19. Each participant who opts in will have baseline (within 3 days of vaccination) serologies obtained and immunogenicity assessment at 28 (+7) days after each dose. All participants will be followed for 180 days after dose 2 for serious adverse events and adverse events of special interest.

NCT ID: NCT05157100 Completed - Cervical Dystonia Clinical Trials

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Start date: October 19, 2021
Phase: Phase 4
Study type: Interventional

Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.

NCT ID: NCT05157087 Completed - Asthma Clinical Trials

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

Start date: March 1, 2020
Phase:
Study type: Observational

A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months

NCT ID: NCT05157074 Completed - Parkinson Disease Clinical Trials

Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease

Start date: January 9, 2019
Phase: N/A
Study type: Interventional

Participants in this study (18-89 years) with Parkinson's disease or Huntington's disease receive drum classes twice a week for 12 weeks (24 lessons). All participants also participate in study visits for assessments before the beginning of the study, at the 6 week mark, at the 12 week mark and at the 18 week mark so that the investigators can assess the short and long term effects of drum classes on hand dexterity, upper extremity function and well-being.

NCT ID: NCT05157048 Completed - Smoking Behaviors Clinical Trials

Acute Cigarette Evaluation Study

SKY Pilot
Start date: March 10, 2022
Phase: N/A
Study type: Interventional

This single laboratory session pilot study will examine the acute effects of commercially available cigarettes on adult smokers' initial product perceptions, use, and exposure. Forty adult daily smokers will be randomized to smoke two study-supplied commercially-available cigarettes interspersed by 45 minutes, completing pre- and post-cigarette carbon monoxide and questionnaire measures.

NCT ID: NCT05156918 Completed - Exercise Clinical Trials

The Effects of High-Intensity Exercise on Biological Age

Start date: November 29, 2021
Phase: N/A
Study type: Interventional

The purpose of this graduate student research study is to determine if a high-intensity exercise program can slow or reverse biological (transcriptomic) aging and shed light on the underlying transcriptomic pathways involved.

NCT ID: NCT05156073 Completed - Dementia Clinical Trials

Shared Decision Making About Medication Use for People With Multiple Health Problems

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

The Shared Decision Making about Medication Use for People with Multiple Health Problems study will assess the feasibility and acceptability of a deprescribing educational intervention in primary care for patients with mild cognitive impairment or dementia and/or multiple chronic conditions (MCC), the patients' care partners, clinicians, and medical assistants. The intervention consists of the following strategies: 1) a patient/caregiver component focused on education and activation about deprescribing, and 2) a clinician component focused on increasing clinician awareness about options and processes for deprescribing in the MCI/dementia and/or MCC population. Clinicians will each be asked to participate in a single, 15-minute educational session on deprescribing, and medical residents will receive a 45-minute lecture. Patients, caregivers, clinicians, and medical assistants will participate in a single one-on-one debriefing interview.